The Food and Drug Administration will conduct a review of the abortion pill mifepristone following intense pressure from Sen. Josh Hawley (R-MO) and anti-abortion advocates to review updated safety information for medication abortions. 

FDA Commissioner Marty Makary wrote in a letter to Hawley on Monday that he is “committed to conducting a review of mifepristone and working with professional career scientists at the agency who review this data.”